^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGB-108

    i
    Other names: BGB-108
    Associations

    News

    Trials
    Company:
    BeOne Medicines
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    17d
    DUBHE-L-303: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=606, Active, not recruiting, Qilu Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • Qibeian (iparomlimab/tuvonralimab) • BGB-108
    8ms
    DUBHE-L-303: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=650, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Dec 2029 | Trial primary completion date: Jun 2025 --> Jun 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • Qibeian (iparomlimab/tuvonralimab) • BGB-108
    almost3years
    A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=650, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • Qibeian (iparomlimab/tuvonralimab) • BGB-108